Ownership and insider activity for Orchestra BioMed Holdings, Inc. (OBIO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures.
Price
| Price | $6.01 |
| Market Cap | $360M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-10 | Hochman David P | F-InKind | 3,283 | $19K |
| 2026-09-10 | Hochman David P | F-InKind | 3,283 | $19K |
| 2026-09-03 | Hochman David P | P-Purchase | 10,000 | $48K |
| 2026-09-01 | Sherman Darren | S-Sale | 15,000 | $74K |
| 2026-08-26 | Taylor Andrew Lawrence | F-InKind | 3,076 | $16K |
| 2026-08-26 | Sherman Darren | F-InKind | 4,925 | $26K |
| 2026-08-26 | Sherman Darren | P-Purchase | 2,000 | $11K |
| 2026-08-26 | Aiello Joshua | F-InKind | 203 | $1K |
| 2026-08-12 | Pacitti David | F-InKind | 3,761 | $17K |
| 2026-08-12 | Fain Eric S | F-InKind | 5,145 | $23K |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.3M | $9.9M | $19.8M | $30.6M | $22.3M | $34.7M |
| Short-term Investments | $15.4M | $958000 | $64.0M | $57.0M | $44.6M | $71.8M |
| Receivables | $168000 | $121000 | $96000 | $99000 | $92000 | $95000 |
| Inventory | $69000 | $68000 | $276000 | $146000 | $173000 | $310000 |
| Total Current Assets | $36.3M | $11.3M | $84.7M | $89.1M | $69.2M | $107.9M |
| Property, Plant & Equipment | $1.0M | $1.1M | $3.7M | $2.8M | $3.5M | $3.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $38.1M | $13.5M | $95.6M | $95.2M | $76.2M | $114.9M |
| Accounts Payable | $1.8M | $2.0M | $4.0M | $2.9M | $5.1M | $6.1M |
| Short-term Debt | $4.0M | $2.0M | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $14.4M | $12.2M | $18.6M | $11.2M | $16.2M | $16.7M |
| Long-term Debt | $5.5M | $3.7M | $9.5M | 0 | $14.3M | $14.3M |
| Total Liabilities | $86.6M | $84.8M | $43.0M | $27.2M | $43.2M | $51.5M |
| Retained Earnings | -$143.1M | -$166.1M | -$199.7M | -$248.9M | -$309.9M | -$362.6M |
| Total Equity | -$48.5M | -$71.2M | $52.5M | $68.0M | $33.0M | $63.4M |
| Total Debt | $9.5M | $5.7M | $11.9M | $1.7M | $16.5M | $16.0M |
| Net Debt | -$26.3M | -$5.2M | -$71.9M | -$85.9M | -$50.3M | -$90.6M |
| Working Capital | $21.9M | -$921000 | $66.1M | $77.9M | $53.0M | $91.2M |
Financial Health
| Debt / Equity | 2.41 |
| Current Ratio | 8.26 |
Profitability
| Return on Equity | -125.93% |
| Return on Invested Capital | -56.28% |
| Return on Assets | -51.02% |
| Gross Margin | 99.32% |
| Operating Margin | -181.36% |
| Net Margin | -184.60% |
Related companies: AVTX · CRBU · ENTA · EPRX · IVA · IVVD · PRLD
Explore sector: Healthcare · Biotechnology
More sections of OBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks